KINETIC PROFILES OF TIANEPTINE AND ITS MC5 METABOLITE IN PLASMA, BLOOD AND BRAIN AFTER SINGLE AND CHRONIC INTRAPERITONEAL ADMINISTRATION IN THE RAT

被引:14
作者
COUET, W
GIRAULT, J
LATRILLE, F
SALVADORI, C
FOURTILLAN, JB
机构
[1] IRIS,6 PL PLEIADES,F-92415 COURBEVOIE,FRANCE
[2] EVIC CEBA,BLANQUEFORT,FRANCE
[3] CEMAF,POITIERS,FRANCE
关键词
pharmacokinetics; rat; Tianeptine;
D O I
10.1007/BF03190130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was conducted to determine kinetic profiles of the antidepressant tianeptine and its main metabolite (named MC5) in plasma, blood and brain after single (10 mg.kg-1) and chronic (10 mg.kg-1.day-1 and 2 × 10 mg.kg-1day-1 for 15 days) intraperitoneal administration in Wistar rats. In plasma, tianeptine and MC5 reached a peak very quickly (5 and 15 mid post administration respectively). Following the peak, disappearance of tianeptine was faster than that of MC5 with terminal half-lives close to 2.5 and 6.5 h respectively. During chronic treatment, accumulation of tianeptine was negligible, that of MC5 was slight as indicated by accumulation ratios equal to 1.28 (once daily administration) and 1.73 (twice daily administration). Tianeptine and MC5 rapidly appeared in brain tissue but at concentrations less than those observed in plasma. Peak concentrations of tianeptine in brain were higher than those of MC5. A very low penetration of tianeptine and MC5 into erythrocytes was observed. © 1990 Springer-Verlag.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 16 条
[1]  
BACCINO E, 1988, 5TH INT M CLIN PHARM, P28
[2]   EVALUATION OF THE LEVELS OF FREE AND TOTAL AMITRIPTYLINE AND METABOLITES IN THE PLASMA AND BRAIN OF THE RAT AFTER LONG-TERM ADMINISTRATION OF DOSES USED IN RECEPTOR STUDIES [J].
BAUMANN, P ;
GAILLARD, JM ;
JONZIERPEREY, M ;
GERBER, C ;
BOURAS, C .
PSYCHOPHARMACOLOGY, 1984, 84 (04) :489-495
[3]  
BOUYER I, 1988, PSYCHOPHARMACOLOGY S, V96, P275
[4]  
CAMPBELL DB, 1981, BIOL PSYCHIAT, P585
[5]  
DEFRANCE R, 1988, CLIN NEUROPHARMACOL, V11, pS74
[6]  
ELMESTIKAWY S, 1988, 5TH INT M CLIN PHARM, P31
[7]  
FILLION G, 1988, PSYCHOPHARMACOLOGY S, V96, P146
[8]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[9]   HYDROPHOBICITY AND CENTRAL-NERVOUS-SYSTEM AGENTS - ON THE PRINCIPLE OF MINIMAL HYDROPHOBICITY IN DRUG DESIGN [J].
HANSCH, C ;
BJORKROTH, JP ;
LEO, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (09) :663-687
[10]  
KATO G, 1988, CLIN NEUROPHARMACOL, V11, pS43